Protalix BioTherapeutics (PLX) Total Liabilities (2010 - 2026)

Protalix BioTherapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $35.1 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 22.39% year-over-year to $35.1 million; the TTM figure through Mar 2026 stood at $35.1 million (up 22.39% YoY), while the FY2025 annual figure was $34.1 million, up 12.94% from the prior year.
• Total Liabilities was $35.1 million for Q1 2026 at Protalix BioTherapeutics, up from $34.1 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $75.9 million in Q1 2022 to a low of $28.6 million in Q2 2025.
• Historically, Total Liabilities has averaged $49.1 million across 5 years, with a median of $49.4 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities grew 27.41% in 2024, then sank 54.6% in 2025.
• A 5-year view of Total Liabilities shows it stood at $66.4 million in 2022, then slipped by 23.43% to $50.9 million in 2023, then plunged by 40.62% to $30.2 million in 2024, then advanced by 12.94% to $34.1 million in 2025, then rose by 2.9% to $35.1 million in 2026.
• The last three Total Liabilities figures came in at $35.1 million (Q1 2026), $34.1 million (Q4 2025), and $29.4 million (Q3 2025), per Business Quant data.